 An adenosine A3 receptor agonist (CF-101) is in clinical trials for the treatment of rheumatoid arthritis.In a mouse model of infarction the A3 selective agonist CP-532,903 protected against myocardial ischemia and reperfusion injury.A number of selective A3 ligands are available.